Skip to main content

Table 1 Demographics, clinical features, responsible pathogens, and outcomes of patients treated with aerosolized colistin

From: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

Characteristic Patient
  1 2 3 4 5 6 7 8
Medical history Fatty liver, arterial hypertension Smoking, arterial hypertension, pulmonary oedema, heart attack, mild chronic renal failure Liver hamartoma, chronic obstructive pulmonary disease, urinary incontinence, hypothyroidism, Sjögren's syndrome, excised left frontal lobe meningioma Catarract, cholosteatoma, arterial hypertension, urinary tract infection 3 weeks before admission Wolff–Parkinson–White syndrome, chronic renal failure (polycystic kidney disease), ankylosing spondylitis Smoking, obesity, chronic obstructive pulmonary disease Arterial hypertension, chronic renal dysfunction (creatinine clearance 75–80 ml/min), adenoma of hypophysis, epileptic seizures, cerebral haemorrhage Arterial hypertension, cerebral arteriovenous malformation
Reason for admission Stomach lymphoma Acute myocardial infarction Epileptic seizures Fever, headache Multitrauma patient, C4–C5 fractures due to car accident, functional dissection of spinal cord, haemothorax Oesophageal perforation Adenoma of hypophysis, cerebral haemorrhage Pneumonia, sleep apnoea syndrome, cerebral haemorrhage
Discharge diagnosis Stomach lymphoma, nosocomial pneumonia Acute myocardial infarction, nosocomial pneumonia Postsurgical intracranial haematoma, pulmonary embolism, inferior vena cava filter placement Pneumococcal meningitis, hydrocephalus, pulmonary embolism, pneumonia, urinary tract infection Septic shock, multiple organ failure Mediastinitis Pneumonia Pneumonia, sleep apnoea syndrome, cerebral haemorrhage
APACHE II score on ICU admission 14 17 17 9 12 17 19 12
APACHE II score on first day of colistin treatment 10 29 19 8 19 20 18 14
Surgery during hospitalization Liver biopsy, partial gastrectomy Coronary artery bypass surgery Drainage of postsurgical haematoma of left frontal lobe, inferior vena cava filter placement Endoscopic ethmoidectomy, surgical drainage of the frontal and maxillary sinuses Spinal arthrodesis surgery (C5–T1) Surgical repair of oesophageal perforation Excision of pituitary adenoma Embolization of arteriovenous malformation
Duration of mechanical ventilation (days) 10 16 5 18 65 25 8 8
Time from ICU admission to develop the infection for which aerosolized colistin was given (days) 8 1 7 22 24 1 7 5
Site of infection Pneumonia (VAP) Pneumonia, urinary tract infection Bacteraemia, pneumonia (VAP) Pneumonia (VAP) Pneumonia (VAP) Pneumonia Pneumonia (VAP) Pneumonia (VAP)
Isolated micro-organism (source) Acinetobacter baumannii (BAL) A baumannii (bronchial secretions) A baumannii (blood), A baumannii (bronchial secretions) Pseudomonas aeruginosa (bronchial secretions) A baumannii (bronchial secretions) A baumannii (BAL) A baumannii (bronchial secretions) A baumannii (bronchial secretions)
Susceptibility of the isolated pathogen MDR (sensitive to colistin and gentamycin) COS COS COS MDR (sensitive to colistin and gentamycin) COS MDR (sensitive to colistin and gentamycin) MDR (sensitive to colistin and gentamycin)
Duration/dosage of nebulized colistin 6 days/1 million IU q8 h 13 days/1 million IU q8 h 10 days/0.5 million IU q8 h 5 days/1.5 million IU q8 h 7 days/2 million IU q8 h 3 days/1 million IU q8 h 8 days/0.5 million IU q6 h 19 days/1 million IU q8 h
Duration/dosage of concomitant intravenous antibiotic treatment Colistin: 2 days/3 million IU q8 h, 6 days/2 million IU q8 h
Levofloxacin: 3 days/500 mg q24 h
Co-trimoxazole: 4 days/3 ampules q8 h
Ciprofloxacin 4 days/400 mg q12 h
Colistin: 14 days/1 million IU q8 h
Meropenem: 12 days/1 g q12 h
Colistin: 26 days/3 million IU q8 h
Meropenem: 26 days/2 g q8 h
She received intravenous colistin before nebulized treatment (7 days/1 million IU q8 h) and after the end of nebulized treatment (32 days/1 million IU q8 h) Tobramycin: 7 days/80 mg q24 h
Aztreonam: 3 days/1 g q8 h
Colistin: 14 days/2 million IU q8 h
Meropenem: 15 days/2 g q8 h
Gentamicin: 8 days/80 mg q8 h
Colistin: 8 days/2 million IU q8 h
Meropenem: 4 days/2 g q8 h
Meropenem: 27 days/2 g q8 h
Gentamicin: 27 days/80 mg q8 h
Duration of hospitalization (days) 17 16 41 234 94 25 36 40
Duration of ICU stay (days) 11 16 21 62 95 25 13 20
Outcome of infection Cure Improvement Cure Improvement Deterioration Improvement Cure Cure
Outcome of patient Discharge Discharge Discharge Discharge Death Discharge Discharge Discharge
Serum creatinine value (mg/dl) on the first day of aerosolized colistin administration 1.1 5.2 1 0.4 2.4 0.6 0.8 0.8
Serum creatinine value (mg/dl) at the end of aerosolized colistin administration 0.8 4.5 0.9 0.5 3.8 0.5 0.7 0,6
  1. APACHE, Acute Physiology and Chronic Health Evaluation; BAL, bronchoalveolar lavage; COS, colistin-only-sensitive; ICU, intensive care unit; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.